-
L. gasseri, NR1I3, and E-Cadherin in Colitis
2026-08-10
Qian and colleagues show that Lactobacillus gasseri ATCC33323 protects against DSS-induced colitis in mice by preserving epithelial barrier function through an NR1I3–CDH1/E-cadherin pathway. The study combines probiotic intervention, intestinal E-cadherin perturbation, barrier and inflammatory readouts, microbiota analysis, and in vitro transcriptional experiments to move beyond an association between probiotics and colitis protection.
-
Sulfo-NHS-SS-Biotin for HBV Entry Assays
2026-08-09
Sulfo-NHS-SS-Biotin enables reversible surface-protein measurements that can clarify how NTCP trafficking and CDC42-dependent uptake shape HBV entry. This guide translates recent mechanistic findings into assay design, controls, and interpretation strategies.
-
Sulfo-NHS-SS-Biotin for Reversible Surface Mapping
2026-08-08
Sulfo-NHS-SS-Biotin combines water-compatible amine labeling with a reducible disulfide spacer, enabling both robust capture and controlled release. It is especially useful for cell surface protein labeling, reversible interactome workflows, and protein or antibody purification where permanent biotin can complicate downstream analysis.
-
Lopinavir: From HIV Potency to Assay Insight
2026-08-07
Lopinavir (ABT-378) is a powerful HIV protease inhibitor whose value extends beyond potency measurements. This article explains how to interpret its resistance profile, serum behavior, formulation requirements, and cross-viral cell-culture evidence without confusing phenotypic activity with a proven mechanism.
-
Firefly Luciferase mRNA (5-moUTP): Optimizing Reporter Assay
2026-08-07
EZ Cap™ Firefly Luciferase mRNA (5-moUTP) redefines bioluminescent reporter workflows with robust, high-yield expression and minimized innate immune activation. Its advanced capping and 5-moUTP modifications enable superior stability and translation efficiency, making it a benchmark for mRNA delivery and functional genomics studies.
-
O-GlcNAcylation Drives Wnt-Induced Glycolysis in Bone Format
2026-08-06
This study uncovers how Wnt signaling stimulates bone formation by activating O-GlcNAcylation, which in turn rewires aerobic glycolysis in osteoblasts. The findings highlight a pivotal metabolic mechanism linking Wnt pathway activity to bone anabolism and suggest new molecular targets for osteoporosis therapies.
-
JNJ-10198409 in Translational PDGF Receptor Research: Beyond
2026-08-06
Explore how JNJ-10198409, a potent platelet-derived growth factor receptor inhibitor, is revolutionizing translational research beyond conventional oncology models. This article delivers advanced insight into its molecular mechanism, unique protocol considerations, and the broader implications for disease modeling and assay innovation.
-
SZQ-3 Modulates Mitochondrial Function to Prevent Osteoporos
2026-08-05
The referenced study introduces SZQ-3, a chromone–maleimide hybrid, as a novel inhibitor of NF-κB signaling that prevents postmenopausal osteoporosis by stabilizing mitochondrial function in bone cells. This dual-action agent suppressed osteoblast apoptosis and osteoclast differentiation, offering a promising therapeutic strategy with demonstrated in vivo efficacy and safety.
-
Sulfo-NHS-SS-Biotin: Cleavable Biotinylation for Protein Pur
2026-08-05
Sulfo-NHS-SS-Biotin is a water-soluble, amine-reactive biotin disulfide N-hydroxysulfosuccinimide ester used for selective, reversible protein labeling. Its unique disulfide spacer enables cleavable biotinylation, facilitating advanced affinity purification protocols. This article reviews its mechanism, benchmarks, and protocol integration, clarifying misconceptions and highlighting practical limits.
-
Optimizing CYP2C19 Assays with (S)-Mephenytoin (SKU C3414)
2026-08-04
This article provides scenario-driven guidance for biomedical researchers and lab technicians seeking reliable, reproducible CYP2C19 substrate assays. By leveraging (S)-Mephenytoin (SKU C3414), scientists can achieve data-backed improvements in cytochrome P450 metabolism workflows, with explicit attention to compatibility, assay sensitivity, and protocol optimization.
-
Imeglimin Improves Mitochondrial Function in Carpal Tunnel S
2026-08-04
This study demonstrates that Imeglimin enhances mitochondrial activity in subsynovial connective tissue cells from patients with idiopathic carpal tunnel syndrome. The findings highlight improvements in mitochondrial biogenesis, antioxidant defense, and reduced apoptosis, suggesting a potential pathway for therapeutic intervention in fibrotic tendon disorders.
-
Upd2 Cytokine Directs Tracheal Stem Cell Migration via JAK/S
2026-08-03
This study reveals that the fat body-derived cytokine Upd2 orchestrates the disciplined, directional migration of adult tracheal stem cells in Drosophila through JAK/STAT-mediated activation of planar cell polarity genes. These results establish a mechanistic link between inter-organ signaling and stem cell trafficking, with implications for understanding tissue homeostasis and regeneration.
-
Omeprazole (A2845): Technical Guide for H+,K+-ATPase Inhibit
2026-08-03
Omeprazole (SKU A2845) is a chemically defined H+,K+-ATPase inhibitor intended for controlled studies of gastric acid secretion and antiulcer mechanisms. It is optimal for in vitro and ex vivo research workflows but is not suitable for diagnostic or clinical applications, nor for long-term storage in solution.
-
Cy7 NHS Ester: Technical Guidance for Near-Infrared Labeling
2026-08-02
Cy7 NHS ester is a sulfonated, hydrophilic near-infrared dye for bioimaging, enabling high-sensitivity labeling of proteins and peptides without organic co-solvents. It is especially suited for applications requiring water solubility and minimal fluorescence quenching, but is not recommended where long-term storage of dye solutions or non-amino group labeling is required.
-
Site-Specific Biotinylation of IL7 Preserves Functionality
2026-08-01
This study establishes a prokaryotic AviTag/BirA biotinylation platform for Interleukin-7 (IL7), enabling the production of site-specifically biotinylated IL7 with minimal loss of bioactivity. These findings have practical implications for protein therapeutics and targeted biotin-streptavidin applications.